Apricus Biosciences Inc Share Price Nasdaq
Equities
US03832V1098
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2022 | - | Sales 2023 | 2.2 175.53 | Capitalization | 13.61M 1.08B |
---|---|---|---|---|---|
Net income 2022 | -73M -5.82B | Net income 2023 | -37M -2.95B | EV / Sales 2022 | - |
Net Debt 2022 | 4.59M 366M | Net Debt 2023 | 11.23M 895M | EV / Sales 2023 | 11,278,477 x |
P/E ratio 2022 |
-0.98
x | P/E ratio 2023 |
-0.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.35% |
Latest transcript on Apricus Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 31/12/86 |
Director of Finance/CFO | 52 | 31/12/18 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 31/08/21 | |
Richard Pascoe
CHM | Chairman | 60 | 28/02/13 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 31/12/18 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |